Výsledky vyhledávání - "Paul H. O'Brien"

Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer

Autor: Shibnath Ghatak, Suniti Misra, Glenn D. Prestwitch, Vincent C. Hascall, Paul H. O'Brien, Markku Tammi, Madhukar Khetmalas, Subhash Padhye, Roger R. Markwald, James B. McCarthy, Nikos K. Karamanos, Raija Tammi, Alok Vyas

Publikováno v: Medicinal Chemistry Research. 23:3836-3851

Inflammatory pathway plays an important role in tumor cell progression of colorectal cancers. Although colon cancer is considered as one of the leading causes of death worldwide, very few drugs are available for its effective treatment. Many studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125c16415d77e4f5de2fdfb06f46b597
https://doi.org/10.1007/s00044-014-0958-4

Zobrazit plný text záznamu

Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: Synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities

Autor: Ajit Zambre, Shibnath Ghatak, K. Venkateshwara Swamy, Subhash Padhye, Madhukar Khetmalas, Victor M. Fresco, Alok Vyas, Roger R. Markwald, Zahra Afrasiabi, Suniti Misra, Amitava Choudhury, Paul H. O'Brien

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 24:317-324

Although dual inhibition of Cyclooxygenase-2 (COX-2) and 5-Lipoxygenase (5-LOX) enzymes is highly effective than targeting COX or LOX alone, there are only a few reports of examining such compounds in case of colorectal cancers (CRC). In the present

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0316eedc52b7c86b90de8c76f24854
https://doi.org/10.1016/j.bmcl.2013.11.015

Zobrazit plný text záznamu

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Autor: Maria Anderson, Danny Rischin, William D. Hanley, Jérôme Fayette, Andrea Pirzkall, Dana Cernea, Tibor Csoszi, Amy V. Kapp, Cristina Oprean, Christopher M. Nutting, Paul M. Harari, Lori J. Wirth, Bruce McCall, Paul H. O'Brien, Anghel Udrea, Elicia Penuel, Jan B. Vermorken, Antonio Jimeno

Publikováno v: Frontiers in Oncology
Frontiers in oncology
Frontiers in Oncology, Vol 6 (2016)

Background: Duligotuzumab, a novel dual -action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0947713d4b817b4bd825be32570349
https://doi.org/10.3389/fonc.2016.00232

Zobrazit plný text záznamu

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Autor: Shaker Dakhil, Swami Murugappan, Paul H. O'Brien, Jun Dong, Kelly S. Oliner, Rita Axelrod, Gabriela Kornek, Philip R. Debruyne, Shubham Pant, Douglas Adkins, Lori J. Wirth

Publikováno v: Oral oncology. 61

This phase 2 estimation study evaluated docetaxel/cisplatin with/without panitumumab, an anti-epidermal growth factor receptor monoclonal antibody, as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).Ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c6e8f4cb9affc1dc62131648b12493
https://pubmed.ncbi.nlm.nih.gov/27688102

Zobrazit plný text záznamu

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer

Autor: Nestor F. Esnaola, Kelly P. Orwat, Paul H. O'Brien, Melanie B. Thomas, Uzair B. Chaudhary, Alberto J. Montero, Joseph Romagnuolo, Brenda J. Hoffman, E. Ramsay Camp, David T. Marshall, Elizabeth Garrett-Mayer, David J. Cole

Publikováno v: International journal of radiation oncology, biology, physics, vol 88, iss 4

Purpose To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced panc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ef351921200b155a3833a67391408a
https://escholarship.org/uc/item/3g77f532

Zobrazit plný text záznamu

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma

Autor: Edward F. McClay, M.-e. T. Mcclay, L Monroe, Paul H. O'Brien, John S. Metcalf, Paul L. Baron, John C. Maize, David J. Cole

Publikováno v: British Journal of Cancer

The adjuvant treatment of high-risk malignant melanoma remains problematic. Previously we reported moderate success in the treatment of metastatic disease using tamoxifen, cisplatin, dacarbazine and carmustine. Based upon data that suggested tamoxife

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71703e6378fccb9406b2b4720f3b06b0
https://doi.org/10.1054/bjoc.1999.1220

Zobrazit plný text záznamu

A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent

Autor: Marina Demcheva, Raymond J. Connolly, Michele W. Chan, Steven D. Schwaitzberg, John N. Vournakis, Paul H. O'Brien, T. Karl Byrne, Paul L. Baron, David J. Cole, John S. Metcalf, David B. Adams

Publikováno v: Surgery. 126:510-517

Background: Topical hemostatic agents are frequently needed for control of intraoperative bleeding. Currently available topical products each have potential drawbacks, making a more effective topical hemostatic agent desirable. This study was perform

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0c86a54b32fc1d15a42b4cce0ebc4fe
https://doi.org/10.1016/s0039-6060(99)70092-9

Zobrazit plný text záznamu

Surgical Management of Unusual Clinical Presentations of Malignant Lymphoma

Autor: Paul H. O'Brien

Publikováno v: Surgical Oncology Clinics of North America. 2:243-250

Unusual presentations of malignant lymphoma are a diagnostic challenge for the surgeon. The role of the surgeon is to acquire an appropriate biopsy. Therapy should be planned by a multidisciplinary team. The role of radical surgery for lymphoma has b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a6997024c814105eab46e0993440e3e
https://doi.org/10.1016/s1055-3207(18)30579-9

Zobrazit plný text záznamu

Melanoma thickness and histology predict sentinel lymph node status

Autor: William E. Gillanders, Christophe L. Nguyen, Paul H. O'Brien, David J. Cole, Ed F McClay, Paul L. Baron, John C. Maize, John S. Metcalf

Publikováno v: American journal of surgery. 181(1)

Background: It remains unclear which patients with melanoma will benefit most from lymphatic mapping and sentinel lymphadenectomy. The purpose of this study is to determine whether primary melanoma histopathologic features could be applied to predict

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d89aa6b8359325823846f1a5151170c8
https://pubmed.ncbi.nlm.nih.gov/11248167

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání